Literature DB >> 11297474

Quality of life associated with unilateral and bilateral good vision.

M M Brown1, G C Brown, S Sharma, B Busbee, H Brown.   

Abstract

OBJECTIVE: To ascertain with patient preference-based methodology whether individuals with good visual acuity (20/20-20/25) in one eye have the same quality of life as individuals with good vision in both eyes.
DESIGN: Cross-sectional comparative study. PARTICIPANTS: Consecutive patients seen in comprehensive ophthalmic and vitreoretinal practices with known ocular disease and good visual acuity (20/20 or 20/25) in one or both eyes.
METHODS: Standardized patient interview. MAIN OUTCOME MEASURES: Time tradeoff and utility analysis values.
RESULTS: The mean time tradeoff utility value in 81 patients with good visual acuity in one eye was 0.89 (standard deviation, 0.17; 95% confidence interval, 0.85-0.93), whereas the mean value in 66 patients with good vision in both eyes was 0.97 (standard deviation, 0.05; 95% confidence interval, 0.97-0.99). The difference between the means of the utility values in these two groups was significant using multiple linear regression (P = 0.001).
CONCLUSIONS: From the patient preference-based point of view, individuals with ocular disease and good visual acuity in both eyes appear to have a higher time tradeoff utility value, and thus a better associated quality of life, than those with good visual acuity in only one eye.

Entities:  

Mesh:

Year:  2001        PMID: 11297474     DOI: 10.1016/s0161-6420(00)00635-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Structure of health-related quality of life among people with and without functional limitations.

Authors:  Willi Horner-Johnson; Rie Suzuki; Gloria L Krahn; Elena M Andresen; Charles E Drum
Journal:  Qual Life Res       Date:  2010-05-14       Impact factor: 4.147

Review 2.  [Value-based medicine in ophthalmology].

Authors:  C Hirneiss; A S Neubauer; C Tribus; A Kampik
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

3.  Comment on the value of vision by Knauer et al..

Authors:  George L Spaeth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-17       Impact factor: 3.117

4.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

5.  Economic and medical benefits of ultrasound screenings for gallstone disease.

Authors:  Hung-Ju Shen; Chung-Te Hsu; Tao-Hsin Tung
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

6.  The burden of age-related macular degeneration: a value-based medicine analysis.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Joshua D Stein; Zachary Roth; Joseph Campanella; George R Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2005

7.  Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6.

Authors:  Eric B Bass; Marsha J Marsh; Carol M Mangione; Neil M Bressler; Ashley L Childs; Li Ming Dong; Barbara S Hawkins; Harris A Jaffee; Päivi Miskala
Journal:  Arch Ophthalmol       Date:  2004-12

8.  The impact of persistent visually disabling vitreous floaters on health status utility values.

Authors:  Haidong Zou; Haiyun Liu; Xun Xu; Xi Zhang
Journal:  Qual Life Res       Date:  2012-10-11       Impact factor: 4.147

9.  Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.

Authors:  Meidong Zhu; Wijeyanthy Wijeyakumar; Adil R Syed; Nichole Joachim; Thomas Hong; Geoffrey K Broadhead; Haitao Li; Kehui Luo; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-30       Impact factor: 3.117

10.  [Visual quality of life after vitreoretinal surgery for epiretinal membranes].

Authors:  C Hirneiss; F Rombold; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2006-02       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.